Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 8/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.54 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | F2R | P25116 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690986 | 1.00 | NTSR1 (0.54) | NTSR1NTSR2BDKRB2OPRD1OPRM1 | |
| SCHEMBL31000886 | 0.97 | NTSR1 (0.55) | NTSR1NTSR2BDKRB2OPRD1OPRM1 | |
| SCHEMBL29611859 | 0.96 | NTSR1 (0.55) | NTSR1NTSR2BDKRB2OPRD1OPRM1 | |
| SCHEMBL32681278 | 0.89 | NTSR2 (0.52) | NTSR1NTSR2OPRM1CAPN1 | |
| SCHEMBL31461890 | 0.87 | CAPN1 (0.53) | NTSR1NTSR2BDKRB2OPRD1OPRM1 | |
| SCHEMBL30733332 | 0.87 | NTSR2 (0.52) | NTSR1NTSR2OPRD1OPRM1CXCR4 | |
| SCHEMBL30102119 | 0.86 | RAMP3 (0.47) | CXCR4 | |
| SCHEMBL30997418 | 0.86 | RAMP3 (0.53) | — | |
| SCHEMBL30602837 | 0.86 | NTSR1 (0.55) | NTSR1NTSR2OPRD1OPRM1 | |
| SCHEMBL30128358 | 0.85 | BDKRB2 (0.48) | NTSR1NTSR2BDKRB2OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134958-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF MAKING THE SAME | AMGEN INC. | 2025-05-01 | — | — | US | disclosed |
| US-12214013-B2 | Methods of treatment of arthritis and/or psoriasis with pharmaceutical formulations of etanercept | AMGEN INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240327453-A1 | METHOD FOR PURIFYING PROTEINS | AMGEN INC. | 2024-10-03 | — | — | US | disclosed |
| US-12070488-B2 | Methods of treating Kawasaki disease | SEATTLE CHILDREN'S HOSPITAL (US) | 2024-08-27 | — | — | US | disclosed |
| US-11952399-B2 | Methods for purifying proteins | AMGEN INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-114917185-B | Pharmaceutical formulations and methods of making the same | 美国安进公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230103554-A1 | TNFa SIGNALING TRIGGERS TUMOR-PROMOTING INFLAMMATION THAT CAN BE TARGETED TO THERAPY | BAYLOR COLLEGE OF MEDICINE | 2023-04-06 | — | — | US | disclosed |
| US-20230080571-A1 | PHARMACEUTICAL FORMULATIONS AND METHODS OF MAKING THE SAME | AMGEN INC. | 2023-03-16 | — | — | US | disclosed |
| EP-4126017-A1 | TNF-ALPHA SIGNALING TRIGGERS TUMOR-PROMOTING INFLAMMATION THAT CAN BE TARGETED TO THERAPY | Baylor College of Medicine (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11491223-B2 | Pharmaceutical formulations and methods of making the same | AMGEN INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220339244-A1 | METHODS OF TREATING KAWASAKI DISEASE | SEATTLE CHILDREN'S HOSPITAL (D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE) (US) | 2022-10-27 | — | — | US | disclosed |
| CN-114917185-A | Pharmaceutical formulations and process for their preparation | 美国安进公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-109982685-B | Pharmaceutical formulations and process for their preparation | 美国安进公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11266744-B2 | Modified Fc molecules | AMGEN INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11253569-B2 | Methods of treating Kawasaki Disease | SEATTLE CHILDREN'S HOSPITAL (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190151463-A1 | MODIFIED Fc MOLECULES | AMGEN INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-9114175-B2 | Modified Fc molecules | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120009205-A1 | Modified Fc Molecules | AMGEN INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151463-A1 | MODIFIED Fc MOLECULES | FCGR1A, FCGRT, FCGR2A | NTSR1 2142/4885NTSR2 2845/4885BDKRB2 2901/4885 |
| US-11266744-B2 | Modified Fc molecules | FCGR1A, FCGRT, FCGR2A | NTSR1 2142/4885NTSR2 2845/4885BDKRB2 2901/4885 |
| US-20120009205-A1 | Modified Fc Molecules | FCGR1A, FCGRT, FCGR2A | NTSR1 2142/4885NTSR2 2845/4885BDKRB2 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.